Bone Metabolism Laboratory, Rheumatology Division, Hospital das Clinicas HCFMUSP, Universidade de Sao Paulo, Sao Paulo, SP, BR, Av. Dr. Arnaldo, 455, 3° andar, sala 3193, São Paulo, SP, 01246-903, Brazil.
Département de médecine, Service de Rhumatologie, Faculté de médecine et des sciences de la santé Université de Sherbrooke, Sherbrooke, Canada.
Osteoporos Int. 2018 Nov;29(11):2565-2573. doi: 10.1007/s00198-018-4629-z. Epub 2018 Jul 13.
The present study investigates the osteoclastogenic capacity of peripheral blood mononuclear cells (PBMCs) in male patients with ankylosing spondylitis (AS). We demonstrated that monocytes from these patients display a lower capacity to generate osteoclasts compared to cells from healthy controls, and osteoclastogenesis was negatively correlated with disease duration.
Ankylosing spondylitis (AS) is a disease characterized by new bone growth that leads to syndesmophyte formation but AS patients frequently present with low bone mineral density/fractures. Osteoclastogenesis in AS patients is poorly studied and controversial. The aim of this study is to determine if the osteoclastogenic capacity of PBMCs is different in AS patients compared to controls and the relationship between osteoclastogenesis and clinical/laboratory parameters.
PBMCs from 85 male AS patients and 59 controls were tested for CD16+ cells and induced to differentiate into osteoclasts over 3 weeks in vitro. Serum levels of RANKL, osteoprotegerin (OPG), C-terminal telopeptide of type I collagen (CTX), and amino-terminal pro-peptide of type I collagen (P1NP) were also evaluated.
PBMCs from AS patients had fewer CD16+ cells and produced fewer osteoclasts compared to controls. Apoptosis occurred less frequently in osteoclasts obtained from AS patients than in osteoclasts from the controls. A lower RANKL/OPG and CTX/P1NP were observed in AS patients compared to controls. AS patients taking NSAIDs presented no difference regarding the number of OCs produced and the percentage of CD16+ cells compared to controls. However, patients taking TNF inhibitors (TNFi) presented lower OC numbers than controls. A negative correlation was demonstrated between the number of osteoclasts generated from PBMCs of AS patients and disease duration.
Monocytes from male AS patients display a lower capacity to generate osteoclasts in vitro compared to cells from controls. Osteoclastogenesis was negatively correlated with disease duration. This finding supports the idea that osteoclasts play a role in the physiopathology of bone disease in AS patients.
本研究旨在探讨男性强直性脊柱炎(AS)患者外周血单个核细胞(PBMCs)的破骨细胞生成能力。我们发现,与健康对照组相比,这些患者的单核细胞生成破骨细胞的能力较低,且破骨细胞生成与疾病病程呈负相关。
强直性脊柱炎(AS)是一种以新骨生长为特征的疾病,导致骨桥形成,但 AS 患者常伴有骨密度降低/骨折。AS 患者的破骨细胞生成研究甚少且存在争议。本研究旨在确定 AS 患者与对照组相比,PBMCs 的破骨细胞生成能力是否不同,以及破骨细胞生成与临床/实验室参数之间的关系。
对 85 例男性 AS 患者和 59 例对照者的 PBMCs 进行 CD16+细胞检测,并在体外诱导分化为破骨细胞,持续 3 周。还评估了血清 RANKL、骨保护素(OPG)、I 型胶原 C 端肽(CTX)和 I 型胶原氨基端前肽(P1NP)水平。
与对照组相比,AS 患者的 PBMCs 中 CD16+细胞较少,破骨细胞生成较少。与对照组相比,AS 患者的破骨细胞凋亡较少。与对照组相比,AS 患者的 RANKL/OPG 和 CTX/P1NP 较低。与对照组相比,服用非甾体抗炎药(NSAIDs)的 AS 患者产生的 OC 数量和 CD16+细胞百分比无差异。然而,服用 TNF 抑制剂(TNFi)的患者产生的 OC 数量低于对照组。AS 患者 PBMCs 生成的破骨细胞数量与疾病病程呈负相关。
与对照组相比,男性 AS 患者的单核细胞体外生成破骨细胞的能力较低。破骨细胞生成与疾病病程呈负相关。这一发现支持了破骨细胞在 AS 患者骨病生理病理中的作用的观点。